News for InspireMD, Inc. (NSPR)

InspireMD (NSPR) has revealed that Michael Lawless will be taking over as Chief Financial Officer (CFO), with the transition expected to occur by the end of Jun

Michael Lawless appointed as InspireMD's (NSPR) new Chief Financial Officer, effective by June 30, 2025. Lawless succeeds Craig Shore, the outgoing CFO

InspireMD, the ticker symbol NSPR, has recently come under the spotlight following an update from the analyst Adam Maeder at Piper Sandler. The firm has maintai

Piper Sandler has revised its price target for InspireMD (NSPR), lowering it from $4.50 to $4, while maintaining an Overweight rating on the stock. This adjustm

Operator: Good morning, and welcome to InspireMD's First Quarter 2025 Earnings Conference call.

Release Date: May 09, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points InspireMD Inc (NS

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NNSPR.OQ - InspireMD IncQ1 2025 InspireMD Inc Earnings CallMay 09, 2025 / 12:30PM GMT =========

InspireMD, Inc. (NASDAQ:NSPR) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ETCompany ParticipantsWebb Campbell – Gilmartin Group LLCMarvin Slosman –...

InspireMD (NSPR) has reported a modest rise in its first-quarter revenue, reaching $1.529 million compared to $1.511 million in the same period last year. The c

InspireMD (NSPR) delivered earnings and revenue surprises of -29.41% and 9.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Management to host investor conference call today, May 9th, at 8:30am ET MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. ( NSPR), developer of the C

MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. ( NSPR), developer of the CGuardâ„¢ Prime carotid stent system for the treatment of carotid artery d

InspireMD (NSPR) will release its first quarter 2025 financial results on May 9, 2025. The company will host a conference call and webcast at 8:30 a.m.

MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. ( NSPR), developer of the CGuardâ„¢ Prime carotid stent system for the treatment of carotid artery d

Revenue (Q4 2024): $1.95 million, a 10.6% increase year-over-year.Full Year Revenue (2024): $7 million, a 13% increase from 2023.Gross Profit (Q4 2024): $469,0

Mar 12, 2025 / 12:30PM GMTOperator Please standby. Your program is about to begin. (Operator Instructions) Hello, and welcome to InspireMD's fourth-quarter 2024

NSPR (NASDAQ:NSPR) Q4 2024 Earnings Conference Call March 12, 2025 8:30 AM ETCompany ParticipantsMarvin Slosman - CEOCraig Shore - CFOShane Gleason -...

InspireMD (NSPR) delivered earnings and revenue surprises of 5% and 6.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[564212]**